This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
In patients with hepatitis B-associated acute-on-chronic liver failure, the plasma biomarkers sCD163 and neutrophil gelatinase-associated lipocalin (NGAL) are independently associated with short-term mortality, according to study results published in Hepatology Research.
The researchers found that sCD163 and NGAL showed strong independent associations with 28-day mortality. However, they did not find a significant association between copeptin and short-term mortality.
The results indicated that incorporating sCD163 and NGAL into the MELD, AARC-ACLF scores, and CLIF-C–ACLF scores resulted in better discrimination and calibration compared with versions of these scoring systems that did not incorporate them.
“The accuracy of risk estimation was improved in both death and survivor groups,” the researchers wrote. “This finding demonstrates a merit of biomarker test in reducing the error of simultaneously underestimating and overestimating mortality risk.”
Read complete article here: https://www.infectiousdiseaseadvisor.com/hepatitis-advisor/hep-b-associated-liver-failure/article/810907/